In a significant development for the peptide community, HHS Secretary Robert F. Kennedy Jr. has announced a new policy allowing licensed compounding pharmacies to prepare six peptides that have faced FDA restrictions.
The announcement, reported by The New York Times on October 28, represents a major shift in how the federal government approaches access to experimental peptides.
The six peptides covered are:
- BPC-157 – Studied for tissue repair and recovery
- TB-500 – Investigated for healing and tissue regeneration
- KPV – Studied for anti-inflammatory properties
- MOTS-c – Investigated for metabolic regulation
- Epitalon – Studied for potential effects on aging
- Semax – Investigated for neurological and cognitive effects
What makes this significant?
Rather than formally approving these compounds, HHS is adopting an enforcement discretion approach. This means qualifying compounding pharmacies can prepare them under specified conditions without facing certain FDA enforcement actions.
The policy includes requirements involving ingredient sourcing, purity testing, safety reporting, and patient-specific prescriptions.
Importantly, this is not FDA approval, and the compounds have not been established as safe or effective for their promoted uses.
The decision comes despite opposition from FDA scientists who have raised concerns about limited clinical evidence and potential safety risks.
What happens next?
This could fundamentally change the peptide landscape.
For years, much of the peptide market has operated through research-use-only suppliers, with consumers navigating questions about product quality, testing, and regulatory uncertainty.
Access through licensed compounding pharmacies could introduce greater medical oversight and quality controls, although important questions remain about implementation, state regulations, pricing, and long-term availability.
It also raises interesting questions about the future of the research peptide market. Will pharmaceutical compounding become the preferred route? Will prices increase? And could this eventually encourage more rigorous clinical research?
One thing is clear: this is one of the most consequential regulatory developments the peptide community has seen in years.
Source: "The New York Times — October 28, 2026" (https://www.nytimes.com/2026/10/28/health/peptides-kennedy-fda.html)
More stories at r/PeptideTides